Dilip Shanghvi, who runs India's most valuable drug company, Sun Pharmaceuticals, maker of generic versions of such drugs as Johnson & Johnson's cancer drug Doxil and Novo Nordisk's anti diabetic drug Prandin, is India's biggest dollar gainer this year, up $4.7 billion. Shanghvi, who moved into the top five last year, is the third richest for the first time. Despite the rise, Sun reported a $210 million loss in the last quarter, after making a provision for settling a patent dispute over Pfizer's acid-reflux drug Protonix. In July, he took over as chairman of Israeli generics firm Taro Pharmaceuticals, a Sun subsidiary, after withdrawing a plan to take it private. Shanghvi started Sun as a maker of psychiatric drugs 30 years ago and grew it in part through acquisitions. His son Aalok who heads international marketing at Sun, cofounded PV Powertech, a maker of solar panels.